Université Clermont Auvergne, Inserm, 3iHP:Service d'Hépato-Gastroentérologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Université Clermont Auvergne, Service de Radiologie, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Aliment Pharmacol Ther. 2021 Mar;53(5):577-586. doi: 10.1111/apt.16232. Epub 2020 Dec 28.
Endoscopic mucosal healing is the current therapeutic target in Crohn's disease. However, transmural healing could lead to better outcomes.
To assess whether transmural healing or magnetic resonance imaging (MRI) healing are better therapeutic targets than endoscopic mucosal healing to predict long-term improved outcome in Crohn's disease METHODS: From our MRI database, we retrospectively identified all Crohn's disease patients who had MRI and colonoscopy within a 3-month interval (median interval = 17.5 days). Four groups were considered: endoscopic mucosal healing (no ulceration or aphthoid erosion), MRI healing (no MRI signs of inflammation and no complication), transmural healing (combination of endoscopic and MRI healing) or no healing. Outcomes were time to surgery, bowel damage progression, hospitalisation, major outcomes (one of the three previous endpoints) and Crohn's disease-related drug discontinuation. Results were expressed in multivariable analyses adjusted on potential confounders (hazard ratio (HR) [95% confidence interval]).
Among 154 patients with Crohn's disease, 51.9% (80/154), 10.4% (16/154), 19.5% (30/154) and 18.2% (28/154) achieved no healing, endoscopic mucosal healing, MRI healing and transmural healing, respectively. Transmural healing (HR = 0.05 [0.00-0.40], P = 0.002) and MRI healing (HR = 0.09 [0.00-0.47], P = 0.005) were associated with lower risk of bowel damage progression than endoscopic mucosal healing. In addition, achieving transmural healing or MRI healing reduced the risk of experiencing major outcomes compared to endoscopic mucosal healing (HR = 0.28 [0.00-0.74], P = 0.01). Patients with transmural healing also had a decreased risk of relapse-related drug discontinuation (HR = 0.35 [0.13-0.95], P = 0.039) compared to those with endoscopic mucosal healing.
Transmural healing and MRI healing are associated with lower risk of bowel damage progression than endoscopic mucosal healing and could be considered as better therapeutic targets in Crohn's disease.
内镜黏膜愈合是目前克罗恩病的治疗目标。然而,黏膜下愈合可能会带来更好的结果。
评估黏膜下愈合或磁共振成像(MRI)愈合是否比内镜黏膜愈合更能预测克罗恩病的长期改善结局,作为更好的治疗目标。
我们从 MRI 数据库中回顾性地确定了在 3 个月内(中位数间隔为 17.5 天)进行 MRI 和结肠镜检查的所有克罗恩病患者。考虑了以下 4 组:内镜黏膜愈合(无溃疡或口疮样侵蚀)、MRI 愈合(无 MRI 炎症迹象且无并发症)、黏膜下愈合(内镜和 MRI 愈合的组合)或无愈合。结局为手术时间、肠道损伤进展、住院、主要结局(上述 3 个结局之一)和与克罗恩病相关的药物停药。结果在调整潜在混杂因素后(风险比(HR)[95%置信区间])进行多变量分析。
在 154 例克罗恩病患者中,分别有 51.9%(80/154)、10.4%(16/154)、19.5%(30/154)和 18.2%(28/154)患者达到无愈合、内镜黏膜愈合、MRI 愈合和黏膜下愈合。与内镜黏膜愈合相比,黏膜下愈合(HR=0.05 [0.00-0.40],P=0.002)和 MRI 愈合(HR=0.09 [0.00-0.47],P=0.005)与较低的肠道损伤进展风险相关。此外,与内镜黏膜愈合相比,达到黏膜下愈合或 MRI 愈合可降低发生主要结局的风险(HR=0.28 [0.00-0.74],P=0.01)。与内镜黏膜愈合相比,黏膜下愈合的患者药物停药的复发相关风险也降低(HR=0.35 [0.13-0.95],P=0.039)。
黏膜下愈合和 MRI 愈合与较低的肠道损伤进展风险相关,比内镜黏膜愈合更能预测克罗恩病的结果,因此可作为更好的治疗目标。